159 related articles for article (PubMed ID: 18626123)
1. Validity of self-reported adherence among injection drug users.
Kerr T; Hogg RS; Yip B; Tyndall MW; Montaner J; Wood E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):157-9. PubMed ID: 18626123
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
4. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill.
Delgado J; Heath KV; Yip B; Marion S; Alfonso V; Montaner JS; O'Shaughnessy MV; Hogg RS
Antivir Ther; 2003 Oct; 8(5):471-8. PubMed ID: 14640395
[TBL] [Abstract][Full Text] [Related]
5. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
6. Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV.
Townsend ML; Jackson GL; Smith R; Wilson KH
Clin Ther; 2007 Apr; 29(4):711-6. PubMed ID: 17617294
[TBL] [Abstract][Full Text] [Related]
7. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting.
Fairley CK; Permana A; Read TR
HIV Med; 2005 Sep; 6(5):366-9. PubMed ID: 16156886
[TBL] [Abstract][Full Text] [Related]
8. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
9. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
Grossberg R; Zhang Y; Gross R
J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
[TBL] [Abstract][Full Text] [Related]
10. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
11. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
12. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
Tyndall MW; McNally M; Lai C; Zhang R; Wood E; Kerr T; Montaner JG
Int J Drug Policy; 2007 Aug; 18(4):281-7. PubMed ID: 17689376
[TBL] [Abstract][Full Text] [Related]
13. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
14. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women.
Kapadia F; Vlahov D; Wu Y; Cohen MH; Greenblatt RM; Howard AA; Cook JA; Goparaju L; Golub E; Richardson J; Wilson TE
Am J Drug Alcohol Abuse; 2008; 34(2):161-70. PubMed ID: 18293232
[TBL] [Abstract][Full Text] [Related]
15. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.
Small W; Wood E; Betteridge G; Montaner J; Kerr T
AIDS Care; 2009 Jun; 21(6):708-14. PubMed ID: 19806487
[TBL] [Abstract][Full Text] [Related]
16. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
[TBL] [Abstract][Full Text] [Related]
17. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
[TBL] [Abstract][Full Text] [Related]
18. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
[TBL] [Abstract][Full Text] [Related]
19. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
Carrieri MP; Villes V; Raffi F; Protopopescu C; Preau M; Salmon D; Taieb A; Lang JM; Verdon R; Chene G; Spire B;
Int J Drug Policy; 2007 Aug; 18(4):288-95. PubMed ID: 17689377
[TBL] [Abstract][Full Text] [Related]
20. Determinants of HAART discontinuation among injection drug users.
Kerr T; Marshall A; Walsh J; Palepu A; Tyndall M; Montaner J; Hogg R; Wood E
AIDS Care; 2005 Jul; 17(5):539-49. PubMed ID: 16036240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
